Last ¥1,390 JPY
Change Today +13.00 / 0.94%
Volume 1.1M
4506 On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
OTC US
OTC US
As of 2:00 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Open
¥1,380
Previous Close
¥1,377
Day High
¥1,395
Day Low
¥1,380
52 Week High
01/10/14 - ¥1,947
52 Week Low
05/27/14 - ¥1,095
Market Cap
553.1B
Average Volume 10 Days
1.0M
EPS TTM
¥52.88
Shares Outstanding
397.9M
EX-Date
09/26/14
P/E TM
26.3x
Dividend
¥18.00
Dividend Yield
1.29%
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and internationally. The company offers various pharmaceutical products, including therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for various therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drug. In addition, the company offers ingredients and additives, which comprise polysaccharides, seasonings, and sweeteners; and chemical product materials consisting of cosmetic materials, active pharmaceutical ingredients, electronic chemicals, and coating materials. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI-608 and BBI-503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

7,015 Employees
Last Reported Date: 06/19/14
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Dainippon Sumitomo Pharma Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Earnings Guidance for the Six Months Ending September 30, 2014 and Full Year Ending March 31, 2015; Provides Interim and Year End Dividend Guidance for the Year Ending March 31, 2015

Dainippon Sumitomo Pharma Co., Ltd. reported consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net income of JPY 5,756 million or JPY 14.49 per share compared to JPY 4,809 million or JPY 12.10 per share a year ago. Net sales were JPY 89,743 million against JPY 89,622 million a year ago. Operating income was JPY 8,694 million against JPY 9,028 million a year ago. Ordinary income was JPY 9,551 million against JPY 9,491 million a year ago. Income before income taxes and minority interests was JPY 11,134 million against JPY 8,490 million a year ago. For the first half of year ending March 31, 2015, the company expects dividend of JPY 9 per share compared to JPY 9 per share a year ago. For the full year ending March 31, 2015, the company expects year end dividend of JPY 9 per share and annual dividend of JPY 18 per share compared to year end dividend of JPY 9 per share and annual dividend of JPY 18 per share a year ago. For the six months ending September 30, 2014, the company expects net sales of JPY 178,000 million, operating income of JPY 12,000 million, ordinary income of JPY 11,500 million and net income of JPY 11,000 million or JPY 27.69 per share. For the full year ending March 31, 2015, the company expects net sales of JPY 352,000 million, operating income of JPY 20,000 million, ordinary income of JPY 19,000 million, net income of JPY 12,000 million or JPY 30.20 per share.

Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Half Year Ending September 30, 2014

Sumitomo Dainippon Pharma Co., Ltd. revised earnings guidance for the half year ending September 30, 2014. For the period, the company revised net sales guidance as JPY 178,000 million compared to JPY 178,000 million previous forecasts. Revised operating income was JPY 12,000 million compared to JPY 12,000 million previous forecasts. Revised ordinary income was JPY 11,500 million compared to JPY 11,500 million previous forecasts. Revised earnings per share were JPY 27.69 compared to JPY 15.86 previous forecasts. Revised operating income was JPY 11,000 million compared to JPY 6,300 million previous forecasts.

Dainippon Sumitomo Pharma Co., Ltd. to Report Q1, 2015 Results on Jul 30, 2014

Dainippon Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2015 results on Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,390.00 JPY +13.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.65 USD +0.08
Eastman Kodak Co $22.50 USD +0.45
FUJIFILM Holdings Corp ¥3,081 JPY -37.00
GlaxoSmithKline Consumer Nigeria PLC 65.99 NGN 0.00
Vanda Pharmaceuticals Inc $12.51 USD +0.21
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 25.7x
Price/Sales 1.4x
Price/Book 1.4x
Price/Cash Flow 15.3x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.